Author:
Wang Shushan,Liu Xiaoyuan,Ge Jianbin
Abstract
In the Han population of Jiangsu Province, China, the poor metabolic phenotype of CYP2D6 has not been found in clinical samples in our hospital. However, intermediate and poor metabolic phenotypes of CYP2C19 have been detected. Even if clinical reaction is observed, it is difficult to attribute them to metabolic enzyme types being single cause. A large number of genes, enzymes, and proteins are involved in the drug’s in vivo processes. The detection of metabolic enzymes requires comprehensive and cautious judgment in combination with other results of drug metabolism. That is to say, in clinical practice, it is necessary to determine to what extent the metabolic enzyme type affects the peak concentration of the drug and the area of the drug time curve. Is drug gene testing required or actionable? Recommendations related to dosage or adverse reactions are required to be clear rather than vague. Based on these, precise personalized treatment can be implemented specifically on individual patients.
Reference9 articles.
1. Qu K, Wang F, Du Z, Wang S, Zhang Z, Shen Y. A novel and sensitive method for determination of amisulpride in human plasma by two-dimensional liquid chromatography. Biomedical Chromatography. 2021;35(10):e5149. DOI: 10.1002/bmc.5149. Epub 2021 May 20
2. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. DOI: 10.1055/s-0043-116492. Epub 2017 Sep 14. Erratum in: Pharmacopsychiatry. 2018;51(1-02):e1
3. Pharmgkb.FdaLabelAnnotations. Available from: https://www.pharmgkb.org [Accessed: August 20, 2023]
4. Wang S, Xu Q , Qu K, Wang J, Zhou Z. CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature. Medicine (Baltimore). 2021;100(45):e27736. DOI: 10.1097/MD.0000000000027736
5. Liu X, Lu YF, Guan X, Zhao M, Wang J, Li F. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochemical Pharmacology. 2016;109:70-82. DOI: 10.1016/j.bcp.2016.03.020. Epub 2016 Mar 25